Shane Thomas Gleason Sells 9,923 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 9,923 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $2.55, for a total value of $25,303.65. Following the completion of the sale, the insider owned 1,116,806 shares of the company’s stock, valued at $2,847,855.30. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Price Performance

NSPR stock opened at $1.00 on Friday. The business has a 50 day simple moving average of $1.38 and a 200-day simple moving average of $1.66. The firm has a market capitalization of $46.84 million, a PE ratio of -1.33 and a beta of 0.82. InspireMD, Inc. has a 1 year low of $0.97 and a 1 year high of $2.93.

Key Stories Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in InspireMD during the first quarter worth $29,000. Virtu Financial LLC acquired a new position in InspireMD during the fourth quarter worth $31,000. XTX Topco Ltd acquired a new position in InspireMD during the fourth quarter worth $30,000. Orbimed Advisors LLC lifted its stake in InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new position in InspireMD during the fourth quarter worth $203,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NSPR has been the topic of a number of recent analyst reports. Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 price objective on InspireMD in a report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Finally, Maxim Group initiated coverage on InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.